What Researchers Did
Researchers retrospectively evaluated the feasibility and efficacy of hyperbaric oxygen therapy (HBOT) for severe vaso-occlusive crises (VOC) in nine sickle-cell disease patients who had not responded to conventional treatment.
What They Found
Pain scores significantly decreased from 3.3 before HBOT to 1.9 twenty-four hours after HBOT (P = 0.002). While morphine dosage increased from 23 mg/day to 35.95 mg/day in the two days prior to HBOT, it tended to be lower one day after HBOT (23 mg/day) and decreased to zero two days post-HBOT (P = 0.004). Two out of nine patients experienced ear pain during compression, leading to session interruption, but without lasting issues.
What This Means for Canadian Patients
Hyperbaric oxygen therapy may offer a potential adjunctive treatment option for Canadian patients experiencing severe vaso-occlusive crises that are unresponsive to conventional pain management. This could lead to faster pain relief and a reduction in opioid use for those suffering from this debilitating complication of sickle-cell disease.
Canadian Relevance
This study was not conducted in Canada and does not have a direct Canadian connection.
Study Limitations
Key limitations include the retrospective design and the very small sample size of only nine patients, which limits the generalizability of the findings.